Statistics from Altmetric.com
In our previous report on anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) during current COVID-19 pandemic, we described our observation of both an incidence-shift with a post-lockdown clustering and an increased incidence rate of AAV diagnoses between February and August 2020 compared with previous years.1
In correspondence to our article, Hakroush et al observed a similar incidence-shift with a post-lockdown increase of AAV diagnoses at their centre. This shift affected patients with less severe symptoms but not critically ill patients requiring intensive-care or intermediate-care treatment. In detail, four patients presented with biopsy-confirmed AAV in the stretch of April–June 2019 (one normal ward, three intensive/immediate care unit), while only one diagnosis was made in the same period in 2020.2 We agree that containment measures such as a lockdown and reduced attendance of hospitals due to fear of infection may delay diagnosis of less-severely affected patients. In contrast to the observations by Hakroush et al, our patients with new diagnosis and relapse were diagnosed either on the normal ward or in an outpatient setting. Estimation of the exact diagnostic delay in our cohort was not possible due to the retrospective nature of our study and in some patients, assessment of the medical history was impossible (ie, patients with dementia),1 but most patients complained about symptoms indicative of vasculitis 1–2 months before a diagnosis was made.
Moreover, a pure delay in diagnosis does not fully explain the high number of de novo diagnoses we observed during COVID-19 outbreak 2020. Meanwhile, three more patients were diagnosed with AAV at our centre in the month of October, all of whom had symptom onset of vasculitis in August or in the beginning of September (details provided in online supplemental table 1). These cases had their disease onset during a period of low but slightly rising numbers of SARS-CoV-2 infections in Tyrol. Since then, new containment measures were introduced due to a ‘second wave’ of COVID-19 and no new AAV case was detected for the past 6 weeks suggesting an inverse correlation between the incidence of COVID-19 and AAV (see figure 1). With 17 AAV cases (de novo and relapsed) during the 6 months post-lockdown period between May and October 2020 the incidence rate per month is approximately 3.5 times higher compared with the previous 5 years (2.8 cases per month versus 0.8 cases per month, respectively). Although this clustering might be influenced in part by delayed diagnosis, other factors may contribute to this phenomenon as well.
One such phenomenon with an influence on the incidence of AAV is changes in the environment. The role of environmental factors related to catastrophic events such as the cargo aircraft disaster in Amsterdam 19923 or the earthquake in Kobe, Japan 19924 is being discussed to trigger autoimmune diseases such as AAV due to air pollution.5 Containment measures during the first lockdown led to a significant decrease of carbon dioxide levels as there was almost no air traffic in Tyrol and the car traffic was reduced by 70%. Another relevant factor is that containment and related measures increase psychological stress, which has an impact on the onset of autoimmune diseases.5 These associations still remain speculative and finally could not be verified.3 6
We appreciate that other centres share our experience that COVID-19 appears to affect the diagnosis of AAV. Further research is needed to verify if AAV incidences are truly rising or if post-lockdown clusters are merely a sign of deferred diagnoses.
Patient consent for publication
This study was approved by the Medical University Innsbruck (1215/2020).
Handling editor Josef S Smolen
Correction notice This article has been corrected since it published Online First. The provenance and peer review statement has been included.
Contributors PG wrote the first draft of the manuscript. AK revised the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.